

FOI 3640

10th March 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Response:

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	7
1.2 Apalutamide (Erleada)	<5
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	0
1.4 Darolutamide (Nubeqa)	9
1.5 Enzalutamide (Xtandi)	127
1.6 Talazoparib (Talzenna)	0
1.7 Docetaxel	0
1.8 Relugolix (Orgovyx, Ryego)	0
1.9 Olaparib (Lynparza)	<5

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	
2.2 Olaparib (Lynparza) for prostate cancer	
2.3 Talazoparib (Talzenna) for prostate cancer	
2.4 Relugolix (Orgovyx) for prostate cancer	

Response:

This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated in Cycle 1 or Dose 1
3.1 Abiraterone (Zytiga or generic abiraterone)	
3.2 Apalutamide (Erleada)	
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	
3.4 Darolutamide (Nubeqa)	
3.5 Enzalutamide (Xtandi)	

Response:

This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q4. How many patients were treated with the following combinations in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

Name of medicine	Total Number patients treated	Number patients received <u>cycle 1 or dose 1</u>
4.1 Darolutamide (Nubeqa) + Docetaxel		
4.2 Darolutamide (Nubeqa) monotherapy		
4.3 Olaparib (Lynparza) + Abiraterone		

Response:

This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
5.1 Abiraterone	
5.2 Enzalutamide	

Response:

This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for

the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Email: foi.team@southerntrust.hscni.net